Download presentation
Presentation is loading. Please wait.
1
Value in Health Regional Issues
Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection Philip McEwan, PhD, Thomas Ward, MSc, Chien-Jen Chen, PhD, Mei-Hsuan Lee, PhD, Hwai-I Yang, PhD, Ray Kim, MD, Gilbert L’Italien, PhD, Yong Yuan, PhD Value in Health Regional Issues Volume 3, Pages 5-11 (May 2014) DOI: /j.vhri Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
2
Fig. 1 Incident cases of confirmed HCC in Taiwan with estimated HCV-related HCC. HCV, hepatitis C virus. Value in Health Regional Issues 2014 3, 5-11DOI: ( /j.vhri ) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
3
Fig. 2 Flow diagram of the MONARCH model. Annual transition probabilities control progression through disease states. HCC, hepatocellular carcinoma; HCV, hepatitis C virus. Value in Health Regional Issues 2014 3, 5-11DOI: ( /j.vhri ) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
4
Fig. 3 Estimated cumulative number of chronic hepatitis C infections with bootstrapped 95% confidence intervals. HCV, hepatitis C virus. Value in Health Regional Issues 2014 3, 5-11DOI: ( /j.vhri ) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
5
Fig. 4 Cumulative estimated prevalence of chronic HCV by fibrosis stage. As of 2012, it is estimated that 23.0%, 19.0%, 14.6%, 22.3%, and 21.1% of the 555,313 patients with chronic HCV are in fibrosis sages F1, F2, F3, and F4, respectively. Value in Health Regional Issues 2014 3, 5-11DOI: ( /j.vhri ) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
6
Fig. 5 Estimated prevalence of chronic HCV with varying ‘minimum incidence caps.’ HCV, hepatitis C virus. Value in Health Regional Issues 2014 3, 5-11DOI: ( /j.vhri ) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
7
Fig. 6 (A) Estimated prevalence of hepatocellular carcinoma and chronic HCV per year. (B) Estimated incidence of liver transplants and liver-related deaths per year. HCC, hepatocellular carcinoma; HCV, hepatitis C virus. Value in Health Regional Issues 2014 3, 5-11DOI: ( /j.vhri ) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.